Skip to main content

Table 4 Medium potency estrogen-progestin therapy and risk of ductal and lobular breast cancer stratified by body mass index

From: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study

Recent BMI

Control group

Ductal cancer

Lobular cancer

 

Never use

Ever use

Never use

Ever use

Never use

Ever use

 

No.

No.

No.

ORa (95%CI)

No.

ORa (95%CI)

No.

ORa (95%CI)

No.

ORa (95%CI)

BMI <22

298

47

126

1.0 (Ref)

49

2.0 (1.2–3.3)

19

1.0 (Ref)

12

3.4 (1.4–8.3)

BMI 22–27

895

132

420

1.1 (0.9–1.4)

114

1.6 (1.1–2.3)

46

0.8 (0.4–1.4)

21

2.2 (1.0–4.6)

BMI >27

514

53

357

1.8 (1.4–2.3)

52

1.9 (1.2–3.1)

56

1.9 (1.1–3.3)

10

2.2 (0.9–5.6)

  1. Exclusive use of medium potency estrogen-progestin therapy, users of more than one kind of menopausal hormone therapy were excluded. Women with unknown age at menopause were excluded. Recent = one year before data collection. aAdjusted for age, age at first birth and age at menopause. BMI, body mass index; CI, confidence interval; OR, odds ratio; Ref, reference category.